cancierge ®

Contact

AI platform Our team Testimonials

info@cancierge.ai About us Home Benefits For whom

Your Cancer.
Your AI-treatment option. In minutes, not months.

Validated treatment options & decision support.

Learn more

Treat cancer effectively.
Increase survival rates.

About cancierge®

Wer wir sind

Cancer doesn’t wait.
Why should you?

Every year, around 20 million people are diagnosed with cancer – one in five will be affected during their lifetime. Yet many lack fast access to reliable, personalized treatment information: appointments with specialists often take 3 to 6 weeks, and in parts of Europe up to 94 days. During this time, 65% turn to generic, non-validated AI tools for answers.

cancierge® makes this knowledge accessible. Clinics often struggle to keep up with the growing volume of national & international guidelines, studies & new findings due to limited time & resources. cancierge® translates scientific evidence into case-specific insights, enabling patients to evaluate their options together with their treating physician in an individual clinical context.

About cancierge

To achieve this, we combine clinical data with oncological expertise to develop an AI-supported platform that assists oncologists in making informed, individualized treatment decisions and offers patients greater guidance throughout the course of treatment.

AI platform for tailored support in choosing breast cancer treatment – developed with key opinion leaders.

For clinics

More efficient tumor conferences. Better decisions.

AI-supported, case-related therapy information to support individual treatment decisions
Targeted support for more structured and faster decision-making processes in tumor conferences
Relief for the medical and healthcare team

For patients

Reliable guidance – anytime, anywhere in the world.

Individual information on treatment options based on personal medical data
Comprehensible presentation of medical content for discussion with your doctor
Greater guidance and certainty when making upcoming treatment decisions

About cancierge

AI platform for tailored support in choosing breast cancer treatment – developed with key opinion leaders.

For clinics

More efficient tumor conferences. Better decisions.

For patients

Reliable guidance – anytime, anywhere in the world.

Your health

in best hands

Our AI helps you make informed treatment decisions.

New approaches to cancer treatment

Supporting therapy decisions

Current scientific findings, combined with patient data, form the basis for structured and evidence-based treatment options. 

Combination of research, practice, and technology

Findings from studies, clinical experience, and AI are continuously incorporated into the decision-making logic.

Cancierge® uses AI-powered analytics to provide faster and more informed individualized treatment options. For clinics and patients. 

Data security as a fundamental principle 

All medical data is processed in compliance with the GDPR and protected by state-of-the-art infrastructure and security technologies. 

Evidence-based
therapy decisions

Supporting patients

Optimal use of clinical data

Individual recommendations for each case

High satisfaction among professionals

Round-the-clock support

Daniel Rüben

Founder & CEO

Daniel is a seasoned entrepreneur with a track record of building, merging, and selling software companies, including a recent sale to a Nasdaq-listed company. His leadership drives the strategic vision of Cancierge.ai, guiding our growth and market expansion.

Prof. Dr. med. Sherko Kümmel

Prof. Dr. Sherko Kümmel is a renowned specialist in breast cancer and heads the Clinic for Gynecology and the BreastCenter in Essen—one of Europe’s leading centers, recognized by the German Cancer Society and designated by the state of North Rhine-Westphalia as a surgical treatment center. With several top awards in breast cancer surgery and treatment, Prof. Dr. Kümmel brings invaluable clinical expertise and acts as a key validator in the development of Cancierge to ensure that our product meets the highest medical standards.

Our team of experts

meet the entire team

for every specialty

meet the entire team

Prof. Peter Schmid

Peter Schmid, Chair of Cancer Medicine at Queen Mary University of London, is a world-leading breast cancer oncologist and lead author of New England Journal of Medicine studies that have redefined standards in triple-negative breast cancer.

Founder & Medical Lead

Medical Lead